# A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Source: https://onco.cc/trials/nct06351631/  
OnCo record `nct06351631` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Bomedemstat in myeloproliferative neoplasms, now recruiting.

## Summary

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) is a phase 3 interventional study registered as NCT06351631, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study. Planned enrolment is 400 participants (estimated). The study started in 2024-05-23 and primary completion is expected in 2034-12-04. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06351631
- Phase: 3
- Setting: A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
- Sponsor: Merck Sharp & Dohme
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06351631: https://clinicaltrials.gov/study/NCT06351631

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- technologies: [LSD1 inhibitors](https://onco.cc/technologies/lsd1-inhibitors/)
- drugs: [Bomedemstat](https://onco.cc/drugs/bomedemstat/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06351631.json